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Abstract 
Dengue is a major global disease requiring improved treatment and prevention strategies. 
The recently licensed Sanofi-Pasteur Denvaxia vaccine does not protect children under the 
age of nine and additional vaccine strategies are thus needed to halt this expanding global 
epidemic. Here, we employed a molecular engineering approach and plant-expression to 
produce a humanised and highly immunogenic Poly-Immunoglobulin G Scaffold (PIGS) 
fused to the consensus dengue envelope protein III domain (cEDIII). The immunogenicity of 
this IgG Fc receptor targeted vaccine candidate was demonstrated in transgenic mice 
expressing human FcγRI/CD64, by induction of neutralising antibodies and evidence of cell-
mediated immunity. Furthermore, these molecules were able to prime immune cells from 
human adenoid/tonsillar tissue ex vivo as evidenced by antigen-specific CD4+ and CD8+ T 
cell proliferation, IFN-γ and antibody production. The purified polymeric fraction of dengue 
PIGS (D-PIGS) induced stronger immune activation than the monomeric form, suggesting a 
more efficient interaction with the low affinity Fcγ receptors on antigen-presenting cells. 
These results show that the plant-expressed D-PIGS have the potential for translation 
towards a safe and easily scalable single antigen based tetravalent dengue vaccine. 
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Introduction 
Dengue infection poses a significant health risk with almost a hundred million cases 
worldwide, of which half a million are severe (Bhatt et al., 2013), characterised by organ 
dysfunction, increased vascular permeability, haemorrhagic fever and dengue shock 
syndrome. To counter this expanding global health threat, better case identification, 
improved patient management and new preventive strategies are all urgently needed. A 
major breakthrough in vaccine development occurred recently with the licensing of the CYD 
tetravalent dengue vaccine in several countries, following two large efficacy trials in Asia and 
South America (Capeding et al., 2014; Watts et al., 1998). However, the Sanofi-Pasteur 
produced Denvaxia (as it is commercially known) is only partially effective against serotype 2 
and most importantly contra-indicated in children under the age of nine (Hadinegoro et al., 
2015), due to suboptimal responses in this age population and risk of antibody-dependent 
enhancement of infection (ADE). Also, while the vaccine has been cautiously endorsed by 
the WHO (Wilder-Smith et al., 2016) there remain a number of other issues with this vaccine, 
including its stability, cost-effectiveness and affordability (Deen et al., 2016; Godoi et al., 
2017; Harapan et al., 2017; Shafie et al., 2017). 
Meanwhile, several other vaccine candidates have either progressed to clinical trials or are 
in the late stages of preclinical development. Thus, one of the most advanced alternatives to 
Denvaxia is the DENVax vaccine developed by Takeda Vaccines Inc (Brewoo et al., 2012; 
Osorio et al., 2011), currently undergoing phase 2 trials in Asia and Latin America (Saez-
Llorens et al., 2017). Similarly, the LAV Delta 30 (NIAD/Butantan) dengue vaccine has 
completed phase 1 clinical trials (Durbin et al., 2011) and is about to enter phase II trials. All 
three aforementioned tetravalent vaccines are based on attenuated viral backbone platforms 
and while this may be an advantage when comparing their performance in different 
geographical areas and age populations, there is a certain element of overlap which may 
lead to common safety, stability and cost-effectiveness issues. There is a need for additional 
and preferably complementary vaccine approaches which could be used instead of or 
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alongside one of the viral tetravalent vaccines to achieve a satisfactory level of protection in 
all subjects.  
Several promising non-live subunit dengue vaccine candidates have been reported, 
including DNA vaccines (Poggianella et al., 2015; Porter and Raviprakash, 2015), 
nanoparticle formulations (Swaminathan et al., 2016) and lipidated dengue antigens (Chiang 
et al., 2016). These and other pre-clinical candidates currently being considered are 
necessary for continuous feeding of the dengue vaccine pipeline until an effective vaccine 
strategy against this global pandemic is finally attained.  Our own approach has been to 
evaluate novel dengue subunit vaccine candidates expressed in genetically modified plants 
and designed to be inherently self-adjuvanting (Kim et al., 2016; Kim et al., 2015). Many 
potential biologics have been expressed in genetically modified plants (Arntzen, 2015) and 
this trend is likely to continue with the increasing demand for cheaper medicines produced at 
large scales. One of the more successful recent examples reaffirming the growing promise 
of plant-made biologics is highlighted by the success story of ZMapp™ as a potentially life-
saving drug during the Ebola outbreak of 2014-2016 (Lyon et al., 2014). Importantly, unlike 
bacteria, plants are capable of performing post-translational modifications in proteins which 
makes them amenable for expression of complex proteins such as antibodies and the Fc-
antigen fusion proteins described here. 
Fusion proteins based on immunoglobulin Fc domain have received considerable attention 
over the past two decades, either as therapeutic tools or potential vaccine delivery platform. 
Currently, Fc-fusion based biologics are some of the biggest profit grossing drugs in 
pharmaceutical industry (Czajkowsky et al., 2012). However, the use of Fc-fusion proteins in 
vaccine development has lagged behind. Indeed, several reports describe the use of fusion 
proteins as vaccine constructs against a number of conditions including infections, allergies 
and cancer (reviewed in (Czajkowsky et al., 2012), but to our knowledge, no vaccine based 
on Fc-fusion proteins has been licensed yet for any of these conditions. 
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Nevertheless, Fc-fusion proteins have considerable vaccine potential, from both an 
immunogenic and a safety point of view. Not only are they inherently safe as non-live, 
protein subunit vaccines, but their potential self-adjuvanting nature means that the need for 
exogenous adjuvants is reduced. The targeting of Fc receptors on antigen-presenting cells 
(APC) leads to enhanced antigen uptake and processing, while their polymeric nature 
provides an additional antigen depot effect, both properties ordinarily conferred by adjuvants 
in conventional vaccines. Modelled on the early work of Mekhaiel et al (Mekhaiel et al., 
2011), we have previously tested the immunogenic potential of the polymeric 
immunoglobulin scaffold (PIGS) as a molecular platform for delivery of the dengue virus 
envelope domain III in mice and found that they were highly immunogenic (Kim et al., 2017). 
Here, we provide important new evidence for the substantial vaccine potential of the fully 
humanised version of the dengue PIGS (D-PIGS) that is critical for translation of this 
technology towards application in humans. 
 
Results 
D-PIGS are immunogenic in human adenotonsillar tissue 
We generated dengue Fc-fusion proteins based on human IgG1 heavy chain and consensus 
EDIII domain of dengue envelope protein, by replacing the variable region with the cEDIII 
and linking it to Cγ2 and Cγ3 domains by a short peptide derived partly from Cγ1 domain and 
partly from the hinge region. The µtp is genetically linked at the C’ terminus. This fusion 
protein can then form monomers or polymers resembling polymeric IgM.  One of the key 
advantages of the Fc-fusion proteins over free antigens is their capacity to bind to the Fc 
receptors on antigen-presenting cells (APC) and thus enhance antigen uptake and 
subsequent processing and presentation. Furthermore, while monomeric Fc-fusion proteins 
can bind only to the high affinity receptor (FcγRI), the polymeric versions (here termed ‘D-
PIGS’) can bind to both high and low affinity receptors (Fig1a) thus substantially enhancing 
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their overall immunogenic potential. We validated this concept by testing the immunogenicity 
of either antigen alone, the monomeric fusion protein or the D-PIGS in human tonsillar tissue 
cell cultures from patients undergoing elective tonsillectomy and with no previous dengue 
exposure. CD4+ and CD8+ T cell proliferative responses in CFSE-labelled cell cultures were 
measured by flow cytometry (gating strategy shown in Supplementary data, Fig.S6) as well 
as IFN-γ production. As shown in Fig.1b, while both the monomer and polymers induces T 
cell responses and IFN-γ production significantly above that induced by cEDIII antigen alone 
(p<0.05 and 0.01, respectively) D-PIGS were significantly more efficient in doing so than the 
monomers (p < 0.05). Moreover, D-PIGS also induced higher antigen-specific IgG response 
in these cultures over 2 week’s incubation period. Taken together, these findings show that 
this fully humanised dengue vaccine candidate is immunogenic in human immune tissues, 
inducing both cellular and humoral immune responses in the absence of exogenous 
adjuvants. 
 
Plant expression and purification of D-PIGS 
Molecular cloning of mouse and human versions of D-PIGS is described previously (Kim et 
al., 2017). Human D-PIGS were transiently expressed in Nicotiana benthamiana plants 
following infiltration with recombinant agrobacteria and purified by protein A chromatography. 
This expression system yielded on average 17 mg protein/kg fresh weight plant tissue. Both 
wild type and a ∆XF glycosylation mutant of N. benthamiana plants lacking fucose and 
xylose glycosylation (Strasser et al., 2004) were used but the latter version was used in all 
experiments due to its enhanced receptor binding function (Supplementary data, Fig.S1). D-
PIGS were analysed by SDS-PAGE electrophoresis and Western blotting, as well as HPLC. 
Under reducing conditions (R), D-PIGS yielded a dominant 40 kDa protein band reactive 
with both anti-dengue and anti-Fcγ antibodies, consistent with a single (S) cEDIII-Fc fusion 
protein chain (Fig.2a, lane 2). However, under non-reducing conditions (NR), additional 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
protein bands were revealed, including an 80 kDa band likely representing the monomer (M), 
and a dominant diffuse band of 160 kDa and above likely representing a mixture of dimers 
(160 kDa) and polymers, (480 kDa expected molecular weight though this could not be 
discerned clearly from the gel due to insufficient resolution). Negative control (wild type plant 
extract, lane 1) and positive controls (lane ‘PC’) represented by recombinant cEDIII and 
human IgG1, were included for comparisons.  
Since the SDS-PAGE analysis revealed a mixture of monomeric/single chain and polymeric 
molecular species in the D-PIGS preparation, we next fractionated the low and high 
molecular weight forms by HPLC (Fig.2c). The HPLC profile indicated presence of several 
protein peaks that corresponded to single chain (S), monomer (M) and polymers (P). These 
could be separated into two main fractions corresponding to a dominant single polymer peak 
and a mixture of monomer and single chain (Fig.2c, middle panel). The retention times for 
these protein fractions were compared to those of molecular weight standard proteins 
(bottom panel) and while M and S eluted as 80 and 40 kDa protein peaks, the polymeric 
fraction presented as approximately a 680 kDa protein, which is somewhat higher than the 
theoretical weight of the D-PIGS hexamer (480 kDa), even when accounting for 12 
carbohydrate chains present on the IgG1-Fc (equating to approximately 36 kDa). The larger 
than expected size of the D-PIGS could be simply an anomaly of the HPLC system and the 
molecular standards we used or perhaps altered behaviour due to the presence of multiple 
carbohydrate chains.  This is partly supported by SDS-PAGE analysis of the separated 
fractions that showed the presence of monomers and single chains in the low molecular 
weight fraction (lane 4), and a diffuse polymeric protein band (lane 3) which is significantly 
smaller than the 970 kDa pentameric IgM (lane 2)(Fig.2b) but bigger than the 380 kDa 
human sIgA (lane 1)(Fig.2b). The separated polymeric fraction was stable and showed no 
degradation or change in the ratio of the two molecular forms (hexamers and higher 
polymers) upon 24 h storage at room temperature, +4 or -20o C (Supplementary data, 
Fig.S2). 
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Analysis of D-PIGS binding to Fc-gamma receptors 
We next tested D-PIGS binding to high and low affinity Fc gamma receptors in comparison 
to human IgG1, by surface plasmon resonance analysis (Biacore). Two assays were 
performed, as illustrated in Fig. 3a. First, increasing concentrations of human CD64 and 
CD16a were used as analytes to measure the kinetics of the FcR / Fc interaction. Both D-
PIGS and hIgG1 displayed rapid binding kinetics and slow dissociation from the high affinity 
receptor CD64 (Fig.3b), resulting in calculated affinity constants well above 109 (right panel 
and Supplementary data Table S1). In contrast, when tested for binding to the low affinity 
receptor CD16a, only D-PIGS displayed prolonged dissociation kinetics in keeping with 
significant binding, whereas hIgG1 dissociated extremely rapidly, indicating a very low 
affinity of binding (right-hand panel). These findings are consistent with previous reports that 
the removal of core fucose in either the plant or mammalian linkages increases affinity for Fc 
receptors including CD16a (Forthal et al., 2010; Shields et al., 2002). 
In order to determine if D-PIGS complexes displayed enhanced avidity in respect to FcR 
binding, we designed a reversed assay layout (Fig. 3a, right panel) with the FcR immobilised 
to the chip via an anti-his antibody and the unfractionated D-PIGS complex supplied in the 
fluid phase (Fig. 3c). A receptor density of 200pg/mm2 was chosen to allow multiple 
interactions between FcRs and Fc domains in the D-PIGS to occur. Due to the extremely 
high affinity of CD64 to hIgG1 and to the D-PIGS (left panel), both samples did not 
dissociate from the surface for the duration of the injection. In contrast, for both low affinity 
receptors, D-PIGS remained bound while hIgG1 dissociated within 5 s (CD32a) or at 58 s 
seconds post injection (CD16a). We repeated this assay with D-PIGS material fractioned by 
HPLC (Fig. 3d), and observed that the polymer fraction was retained to CD16a (time to 50% 
dissociation >600 s) while the M/S fraction was released with a similar decay profile to hIgG1 
(time to 50% dissociation 61 s and 58 s, respectively). Interaction with CD32a and the high 
affinity receptor CD64 were also markedly stabilised in the polymeric fraction 
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(Supplementary data Tables S1 and S2). These data show that D-PIGS polymers are 
capable of establishing long lasting interactions with low affinity Fc receptors. 
 
In vitro characterisation of D-PIGS 
D-PIGS were tested for capacity to bind to C1q component of the complement and to the 
U937 monocyte cell line expressing the Fc gamma receptors. As shown in Fig.4a, D-PIGS 
bound to C1q component of the complement in the concentration dependent manner, as 
would immune complexes do, while monomeric hIgG1 did not. Interestingly, purified 
polymers bound better than the unfractionated D-PIGs while the monomer/single chain 
fraction showed little to no binding, as expected. This finding confirms the presence of 
functional polymers in the D-PIGS preparation and is an indication of their immunogenic 
potential. Furthermore, D-PIGS bound efficiently to the surface of U937 cells (used here as a 
model APC) and this binding was comparable to that of heat-aggregated human IgG (AHG) 
(Fig.4b). Though hIgG1 also showed some binding (due to the presence of CD64 on these 
cells), this was significantly weaker compared to D-PIGS. However, in a direct comparison 
between unfractionated and fractionated D-PIGS, no significant differences could be 
observed in binding to U937 cells (Supplementary data, Fig.S3a). Taken together, these two 
in vitro assays demonstrate the functionality of D-PIGS and their capacity to interact with the 
immune cells and molecules. 
 
IgG response after immunisation of CD64 transgenic mice with D-PIGS 
Having confirmed the functionality of D-PIGS molecules in vitro, we next tested their 
immunogenicity in mice transgenic for human high affinity receptor CD64. Mice were 
immunised three times in total and after each immunisation blood samples were taken for 
analysis of serum IgG responses. As can be seen in Fig.5a, no significant responses were 
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detected after the first immunisation for any of the experimental groups. However, after 
second immunisation IgG was detected in all groups except in mice immunised with cEDIII 
alone or in wild type mice immunised with D-PIGS. The response was further enhanced after 
the third immunisation, with the groups co-administered with alum showing the highest 
responses at the serum dilution used (1:1000). Interestingly, D-PIGS induced a low level 
response in wild type mice, possibly due to cross-reactivity with mouse Fc receptors or other 
immune complex capturing mechanisms. We next determined end-point titres in the immune 
sera (Fig.5b) and these were 1:9000 for cEDIII alone and 1:81000 for D-PIGS with or without 
alum. Similar to D-PIGS, the monomeric form also induced a comparable IgG response in 
CD64 transgenic mice, signifying the role of the high affinity receptor in mediating uptake of 
these fusion proteins (Supplementary data, Fig.S3b). We further analysed the relative 
proportion of IgG1 and IgG2a subtypes in the IgG response, which is an indication of Th2 or 
Th1 bias. As shown in Fig.5c and d, IgG1 showed significantly higher end-point titres 
compared to IgG2a which suggests a possible Th2 bias, though some Th1 response at least 
is also evident. 
 
DENV neutralising capacity of D-PIGS induced antibodies 
Since neutralising antibodies are an essential component of a protective immune response 
against dengue infection, we next tested the neutralising potential of the immune sera 
against all four serotypes of the dengue virus. This was performed in the standard plaque 
reduction assay by determining FRNT50 values against each serotype. The results are 
shown in Fig.6. Sera from mice immunised with cEDIII alone showed neutralising potential 
only against DENV4 (4/5) while failing to neutralise any other serotypes. Sera from mice 
immunised with D-PIGS showed a superior neutralising potential against all serotypes, 
though DENV3 was neutralised robustly by serum from one animal only while other four 
animals showed borderline neutralising activity (50% inhibition was achieved only with the 
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first serum dilution of 1:50). The titration curves show the range of FRNT titres and serum 
dilutions. The titres of all the non-neutralising mice were scored arbitrarily as 1:25 with 50 
being the minimum starting serum dilution. Overall, the D-PIGS vaccinated mice exhibited 
strong neutralising antibodies titre with mean titre of 1:257 (1:68-1:636) for DENV1, 
1:115(1:70-1:218) for DENV2, 1:233 (1:50-1:970) for DENV3 and 1:899 (1:79- 1:1440) for 
DENV4. In contrast, although mice immunised with D-PIGS with alum showed comparable 
antibody titres to D-PIGS alone, this was not reflected in enhanced neutralising activity, 
which in fact was lower. Similarly, addition of alum did not increase DENV neutralising 
activity of sera despite increased antibody titres (Supplementary data, Fig.S4). It appears 
that the presence of alum somewhat diminished the neutralising activity of the immune sera, 
possibly reflecting qualitative differences conferred by the two immunisation regimens. 
 
Cellular immune response to D-PIGS immunisation 
We next investigated cellular responses to our vaccine. Emerging evidence suggests that 
polyfunctional T-cells in particular play a protective role in dengue immunisation (Yauch et 
al., 2009). Therefore CD4+ and CD8+ T-cells were assessed for production of combinations 
of the effector cytokines IFN-γ, IL-2, IL-17A and TNF-α after antigen recall (gating strategy 
shown in Supplementary Fig.S5). As can be seen in Fig. 7a, cEDIII alone induced 20.9% 
and 6.29% CD4+ and CD8+ polyfunctional T-cells, respectively. A striking observation was 
the total lack of quadruple cytokine producers in the CD8 compartment. Interestingly, the 
monofunctional phenotype in the cEDIII immunisation group was defined by a strong IFN-γ 
signature. D-PIGS alone induced 22.91% CD4+ and 7.79% CD8+ polyfunctional T-cells, and 
this was enhanced even further with adjuvant, leading to an increase of 24.86% CD4+ and 
18.39% CD8+ polyfunctional T-cells.  
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Given the importance of CD8+ T-cells in protection against DENV - and the observation that 
D-PIGS induced quadruple cytokine producing cytotoxic cells - we further probed the CD8+ 
memory T-cell compartment in response to D-PIGS immunisation. Splenocytes from 
immunised mice were cultured for several more days in the presence of recall antigen or 
positive control (recombinant anti-CD3 antibody) and then assessed for expression of the 
proliferation marker Ki67. As shown in Fig. 7b, there was a dramatic increase in the overall 
percentage of proliferating cytotoxic cells in splenocytes from mice immunised with D-PIGS 
compared to cEDIII antigen alone (13.4% Ki67+ vs 28.4% Ki67+ cells, respectively). 
Consistent with the polyfunctionality, this was further boosted in the alum immunisation 
group (34.2% Ki67+ cells), though cEDIII adjuvanted with alum showed a comparable 
increase in proliferation (32.6 %). Proliferating cells were then examined for memory T-cell 
phenotype, using CD44 and CD62L to denote T central memory (TCM: CD44hiCD62Lhi), T 
effector memory (TEM: CD44hiCD62Llo) and naïve T cells (TN: CD44loCD62Lhi). While there 
were only minimal differences in the percentages of proliferating TEM cells between 
immunisation groups, there was an approximately four-fold increase in the percentage of 
proliferating TCM cells in D-PIGS (± alum) compared to cEDIII alone. Lastly, it was found that 
enhanced proliferation was associated with a higher quantity of secreted IFN-γ in the recall 
culture (Supplementary data, Fig.S3c). It was therefore concluded that D-PIGS increased 
the both the quality and magnitude of the cellular response, as evidenced by increased T-
cell function and proliferative capacity of various memory subsets. 
 
Discussion 
We describe a novel vaccination approach against dengue infection based on Fc-antigen 
fusion approach. We previously expressed dengue PIGS molecules based on murine IgG2a 
and showed that they were highly immunogenic in mice (Kim et al., 2017). To translate this 
promising vaccine approach into a potential dengue vaccine candidate in humans, we 
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generated the human version of dengue PIGS (D-PIGS) and purified them to a high degree 
of homogeneity. D-PIGS were highly immunogenic in transgenic mice expressing human 
IgG high affinity receptor and more importantly in human tonsil cultures. Thus D-PIGS 
induced T cell memory responses, IFN-γ production and neutralising antibodies against all 
four DENV serotypes. This non-live, subunit dengue vaccine based on the consensus EDIII 
domain and human IgG1 polymeric scaffold, has many potential advantages over the other 
vaccination platforms, including simplicity of production, easy scalability, minimal risk of 
contamination with animal pathogens and most importantly, it does not suffer from antigenic 
interference typically associated with a conventional tetravalent vaccine. The latter 
advantage is conferred by the use of consensus domain III sequence that is expressed as a 
single protein fused to human IgG1-Fc. 
The role of EDIII in inducing neutralising antibodies is somewhat paradoxical, in that human 
sera from dengue patients appear to contain only a low proportion of such antibodies 
directed to EDIII (Chen et al., 2016; Wahala et al., 2009; Williams et al., 2012) and yet, there 
are a number of strongly neutralising monoclonal antibodies reported (Crill and Roehrig, 
2001; Roehrig et al., 1998; Shrestha et al., 2010; Sukupolvi-Petty et al., 2007). While most of 
these monoclonal antibodies target linear epitopes, some of the strongly neutralising mAbs 
such as 2D22 target a quaternary epitope on EDIII (Gallichotte et al., 2015). Similarly, rabbit 
antisera targeted to EDIII was strongly neutralising and induced very little ADE, suggesting 
that EDIII may be used as a subunit vaccine to induce an effective and safe antibody 
response. This is consistent with the concept of unnatural immunity, whereby natural 
infection does not seem to provoke neutralising anti-EDIII response while increasing the risk 
of cross-reactivity and ADE, and yet a vaccine induced EDIII antibodies may confer 
protection. Indeed, a study of human anti-dengue neutralising antibodies showed that they 
predominantly recognise complex epitopes present on the intact virions but not recombinant 
envelope ectodomain protein (de Alwis et al., 2012). In this study, we used a consensus 
domain III (Leng et al., 2009) obtained by alignment of amino acid sequences from different 
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isolates of the four serotypes of dengue viruses, rather than the mixture of four individual 
serotype-specific domains, thus simplifying significantly the vaccine formulation.  
D-PIGS induced strong antibody responses in transgenic mice expressing human IgG high 
affinity receptor (CD64). Though both IgG1 and IgG2a were present, a much higher titre of 
IgG1 was detected, suggesting a Th2 bias. Both monomeric and polymeric D-PIGS were 
immunogenic in mice (Supplementary Fig. S3b). This is in contrast with human immune 
response in tonsil cultures which indicated polymer superiority in inducing an IgG response 
and could be explained by only partial suitability of the transgenic CD64 mouse model. As 
both monomer and polymer can bind to high affinity IgG receptor but only polymer binds to 
the low affinity receptors, the single receptor transgene model may not be sufficiently 
discriminatory, unlike the human tissue, which displays all the IgG receptors.  Nevertheless, 
the induced mouse cEDIII-specific antibodies were able to neutralise dengue serotypes 1,2 
and 4 with similar efficiency, with only DENV3 showing lower FRNT values.  Interestingly, 
despite inducing higher antibody titres to D-PIGS, addition of alum as the adjuvant did not 
enhance neutralisation potential of induced antibodies and in fact, appeared to have a 
detrimental effect. Although we have no experimental evidence, we speculate that this is 
most likely due to qualitative differences in the functionality of the induced antibodies.  
The importance of T cell responses in dengue infection has been very much in focus 
recently. While effector T-cells are partially responsible for the immunopathology of dengue 
disease, effective vaccine-induced protection depends on these cells. This was elegantly 
demonstrated in experiments by Yauch et al., (Yauch et al., 2009) who showed that 
depletion of CD4+ T-cells during natural infection had no effect on viral control, whereas 
depletion of this subset during DENV peptide immunisation led to a total loss of vaccine-
induced protection. Dengue induces a number of CD4+ T and CD8+ T cell epitopes to both 
structural and nonstructural proteins recognised in mice (Rothman et al., 1996) and humans 
(Weiskopf et al., 2015b; Weiskopf et al., 2015c). CD8+ T cell responses (particularly of a 
polyfunctional phenotype) are generally thought to play an important role in controlling 
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infection and thus the severity of the disease, partly supported by experimental evidence (Gil 
et al., 2014; Gil et al., 2009; Yauch et al., 2009). Although non-structural proteins are the 
dominant targets of the CD8+ T cell responses (Weiskopf et al., 2013), some CD8+ T cell 
epitopes are present in DIII of the envelope protein (Chiang et al., 2016; Weiskopf et al., 
2015a). In our studies, we detected cEDIII specific both CD4+ and CD8+ T cell proliferation in 
tonsillar cell populations stimulated in vitro. This proliferative response was associated with 
IFN-γ production. Interestingly, polymeric D-PIGS were more efficient in inducing these 
cellular responses than the monomeric version, most probably due to a more efficient 
binding of the Fc receptors, as demonstrated in our in vitro Biacore assays. In our in vivo 
experiments, D-PIGS were more adept than single antigen at producing proliferative TEM and 
TCM responses, alongside increased IFN-γ production and a greater degree of 
polyfunctionality. TCM are of particular interest since these memory cells can serve as a long-
lasting reservoir of immunological memory with high proliferative capacity. Together these 
human and mouse cellular data underscore the immunological superiority of D-PIGS over 
single antigen immunisation. 
 
The advantages of plants as an expression system have been well documented. One of the 
key advantages is the capacity for almost enormous scale up production of pharmaceutical 
proteins which may be required to meet ever increasing global demand. Existing microbial 
systems simply cannot meet that demand because they are either very expensive, or the 
proteins of interest, such as antibodies and the Fc fusion proteins described here, are too 
complex to be made in such systems. Animal or human cell cultures provide an alternative, 
but are expensive. Like animals, plants are complex, multicellular organisms and their 
protein synthesis is more similar to that of animals than those of bacteria or other bio-
microorganisms. To further reduce differences in post-translational modification of plant 
expressed proteins, various genetic plant mutants have been generated, including the delta 
XF tobacco line used in this study. Glycoengineering in plant is developed for 
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pharmaceutical products and well documented (Forthal et al., 2010; Strasser, 2016). Thus, 
Strasser et all (Strasser et al., 2004) produced a triple knockout in Arabidopsis, that down 
regulates β-(1,2) XylT and α-(1,3) FucT activity, resulting in the absence of plant-specific 
glycans which are occasionally involved in inducing glycan-specific IgE (Reusch and Tejada, 
2015), and a product that is much more similar to human glycoproteins. D-PIGS without 
plant-specific fucose and xylose show higher affinity for FcγRIII than D-PIGS from wild type 
N. benthamiana and this is consistent with the findings from another study reporting 
enhanced binding to human FcγRIII and antibody-dependent cellular toxicity on glyco-
engineered human IgG1 (Shields et al., 2002). The D-PIGS molecules produced in delta XF 
plants as described here could therefore be feasibly produced and purified to a high degree 
of purity and homogeneity to meet the good practice manufacturing requirements for safe 
human applications. 
 
In conclusion, we described a novel plant-expressed subunit vaccine candidate for dengue 
vaccination based on Fc-antigen fusion protein approach that could potentially be used as a 
boost to a viral-based dengue vaccine. Humanised D-PIGS show a desirable immunogenic 
profile in mice transgenic for human IgG-Fc receptor and in human tonsil tissues and 
importantly, induce neutralising antibody responses and cellular immunity, which are both 
required in a protective anti-dengue response. This novel dengue vaccine candidate merits 
further evaluation as a boost to Denvaxia or DenVAX in the non-human primate model of 
dengue infection, to achieve complete protection against all for DENV virus serotypes.  
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Materials and Methods 
Plant expression, detection, purification and fractionation of D-PIGS   
Vector construction for D-PIGS, agro-infiltration of Nicotiana benthamiana plant leaves, 
purification and detection by SDS-PAGE and Western blotting, as well as fractionation of low 
and high molecular weight forms were all described in detail previously (Kim et al., 2017). 
Briefly, the agrobacteria (GV3101 strain) transformed with D-PIGS constructs and human J 
chain (co-expression to facilitate the assembly of PIGS into polymers) were cultured at 28 ˚C 
in YENB medium containing antibiotics (50 μg/mL each of carbenicillin, kanamycin and 
rifampicin) for 2 days. Cells were collected by centrifugation and infiltrated into tobacco 
leaves. Leaf extracts were prepared 7 days later and proteins separated on a 4-12 % Bis-
Tris SDS-PAGE gel (Life Technologies), followed by Coomassie Blue staining or blotting 
onto a nitrocellulose membrane.  Blots were probed with peroxidase-conjugated anti-human 
IgG antiserum (1:1000 dilution; The Binding Site) for detection of the IgG Fc portion, or with 
anti-dengue virus monoclonal antibody (1:2500 dilution; Bio-Rad AbD Serotec) followed by 
anti-mouse IgG peroxidase-conjugated antiserum (1:1000 dilution; The Binding Site). For 
purification of D-PIGS, standard protein A chromatography procedure was applied, followed 
by concentrating the protein by ultrafiltration (Centricon) to 1 mg/ml. For some experiments, 
purified D-PIGS were fractionated by HPLC on a Shimadzu LC2010AHT system (Milton 
Keynes, UK). Separation was achieved in phosphate buffered saline (PBS) at a flow rate of 
1 ml/min. As reference, the BioRad GFC Standards were used.  
  
FcγR binding kinetics 
The affinity and avidity of the D-PIGS complexes in binding to human Fcγ receptors were 
measured using a Biacore X100 instrument (GE Life Sciences, Little Chalfont, UK). For the 
affinity measurements, 5000 relative units (RU) of a protein A (Sigma P6032) in pH 5.5 
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acetate buffer (GE Life Sciences) was immobilized on both flow channels of a CM5 sensor 
chip using amine coupling chemistry (His capture kit, GE Life Sciences). For each cycle, 200 
RU of the sample (PIGS or hIgG1) was captured on flow channel 2. The analyte, either 
recombinant human CD16a (4325-FC, R&D Systems) or recombinant human CD64 (1257-
FC-050, R&D Systems) was injected in a concentration series from 12.5 to 800 nM over both 
flow channels with a contact time of 60 s and a flow rate of 50 μl/min, and dissociation 
monitored for 200 s. Regeneration of the surface was achieved by two 30 s pulses of 10 mM 
glycine pH 1.5. 
Data was fitted to the pre-defined ‘two-state interaction’ model for CD16a (Heider et al., 
2011)and the ‘1:1 interaction’ model for CD64. 
 
For the avidity assay, 12000 RU of an anti-his antibody was immobilized on both flow 
channels of a CM5 sensor chip using amine coupling chemistry (His capture kit, GE Life 
Sciences). For each sample, recombinant human CD16 or CD64 (as above) diluted to 2 
μg/ml in HBS-EP+ running buffer was captured on flow channel 2 to a level of 200 RU. 
Samples (1μM, 500nM and 166.7nM for CD64, CD32a and CD16a, respectively) were 
injected over both flow channels with a contact time of 80 s and a flow rate of 30 μl/min, and 
dissociation monitored for at least 500 s. Regeneration of the surface was achieved by a 30 
s pulse of 10 mM glycine pH 1.5. 
 
Immunisation of mice 
For immunisation with D-PIGS, 12-20 weeks old inbred male and female FcγRI/CD64 mice 
were used. These mice were originated in 1996 (Heijnen et al., 1996) and a colony is kept 
and bred at St George’s since 2010 under the establishment licence. The mice were kept 
under defined environmental conditions and all experimental work was approved by St 
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George’s Ethics Committee and the UK Home Office. Five mice per group (both males and 
females, age 8-20 weeks) were immunized subcutaneously in the base of tail with 25 μg of 
D-PIGS in 100 μL, with or without Aluminum hydroxide Gel (Sigma). Control mice were 
immunised with saline solution or with 6 μg cEDIII alone (equivalent amount of the antigen 
within D-PIGS). Mice were immunised two more times, at week 2 and 4, and were bled after 
each immunisation to monitor the antibody titres. At week 6, mice were sacrificed and bled 
by cardiac puncture and the spleens were collected for analysis of T cell responses. 
 
Focus reduction neutralisation test   
Neutralization capacity of sera samples against Dengue 1 – 4 (DENV1 West Pac/74 – Nauru 
1974; DENV2 S-16803 – Thailand 1974; DENV3 CH 53489 – Thailand 1973; DENV4 TVP-360/ 
S341750 – Columbia 1982) was determined by focus reduction neutralisation test (FRNT) on 
Vero cells (ATCC) seeded in 96-well flat-bottom plates at a density of 20,000 cells/ well in 
DMEM medium supplemented with 10 % FBS. Cells were cultured for 24h before infection. 
Sera was thawed and heat inactivated at 56oC for 30 mins and serially diluted from 1:25 to 
1:3200 in 100 μl Opti-MEM (Invitrogen) serum-free medium and an equal volume of dengue 
virus containing 200 PFU was added and incubated for 1h at 37°C in 96 well U bottom cell 
culture plates. Vero monolayer was then infected with 50 μl of the serum-virus mixture and 
further incubated for 1h at 37°C making the final serum dilution to 1:50 in the first well and 
final PFU to 100. The cells were incubated at 37oC for 3 days with an overlay of 2% 
methylcellulose (Sigma) in Opti-MEM containing 20 μg/ml of Ciprofloxacin (Sigma) and 2.5 
μg/ml of amphotericin B (Himedia). At termination, cells were fixed and stained with anti-
Flavivirus Group Antigen Antibody, clone D1-4G2-4-15 (Millipore) at 1:2500 dilution followed 
by HRP-linked anti-mouse IgG (Cell Signalling). Foci were developed with True Blue 
Peroxidase (KLP). Separate Plates were used for each serotype to account for different time 
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intervals required for color development. FRNT50 was calculated where 50% reduction in foci 
was observed as compared to control wells (virus only). 
 
Intracellular cytokine staining and flow cytometry  
T-cell polyfunctionality was measured as previously described (Kim et al., 2017). Briefly, 
splenocytes were stimulated with 5 μg/mL cEDIII for 4 hours in the presence of 5 μg/mL 
brefeldin A. Cells were then washed with PBS and stained with a viability dye (eFluor 780, 
1:1000 dilution; eBioscience) alongside an Fc receptor blockade (TruStain, 1 μg/mL; 
Biolegend) for 20 minutes at 4°C. Following this, cells were washed in flow cytometry buffer 
and then fixed in 100 μL BD Cytofix (Becton Dickinson) for 30 minutes at 4°C. Cells were 
washed and then stained with the following antibodies at optimised concentrations for 45 
minutes at 4°C: CD3-FITC, CD4-PerCP-Cy5.5, CD8-Alexa Fluor 700, IFN-γ-PE Dazzle, IL-2-
PE, IL-17A-PE-Cy7 and TNF-α-APC (all from Biolegend). Fluorescence-minus-one (FMO) 
and PMA/ionomycin-stimulated cells were used to determine gating boundaries and serve as 
positive controls. Cells were then washed twice with permeabilisation buffer and flow 
cytometry buffer, and then acquired on a BD LSR II instrument. 
 
Immune responses to D-PIGS in human adenoid-tonsillar tissue culture ex vivo  
Adenoids and palatine tonsils were obtained from patients (age 3-30 years) who underwent 
the adenoidectomy and/or tonsillectomy due to upper airway obstruction at Liverpool Alder 
Hey Children’s Hospital and Royal Liverpool and Broadgreen University Hospitals (REC 
approval reference: 14/SS/1058). Written informed consent was obtained from each patient. 
Adenoid-tonsillar mononuclear cells (MNC) were isolated following Ficoll gradient 
centrifugation. For detection of T cell proliferative responses, the MNC were stained with 
Carboxyfluorescein succinimidyl ester (CFSE), followed by cell stimulation with the D-PIGS 
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(25 μg/ml) or with cEDIII antigen alone (5 μg/ml). At day 3, cell culture supernatants were 
collected for IFN-γ analysis by ELISA. At day 5, flow cytometry was performed to analyse 
CD4+ and CD8 + T cell proliferative responses using CFSE (5(6)-Carboxyfluorescein N-
hydroxysuccinimidyl ester) cell tracing (Zhang et al., 2007). Lymphocyte population was first 
gated using typical forward and side scatter properties as indicated in Supplementary 
figure S6 (which typically gave a viability greater >95% confirmed by propidium iodide 
staining). Singlet population was gated and followed by sequential staining for 
CD3/CD4/CD8/IFN-γ as shown. Flowjo software was used for flow data analysis. For 
detection of B cell antibody production, tonsillar MNC were stimulated by the vaccines or 
antigens for up to 2 weeks. Cell culture supernatants were harvested and analysed by a 
standard ELISA procedure as described previously (Zhang et al., 2006) for cEDIII antigen-
specific IgG antibody responses. 
 
Additional methods: Binding of D-PIGS to U937 monocytic cells and C1q in ELISA (Text 
S1), humoral responses analysis in sera (Text S2) and T cell proliferation assay and IFN-γ 
measurement (Text S3) are described in Supportive information file.  
 
Statistical analysis 
The cell culture based assays were performed in triplicates and the values (from a 
representative experiment of typically 3 performed, are shown as the mean +/- standard 
deviation. For immunisation experiments, 5 animals were used per group (in two 
independent experiments). For all assays which had more than two experimental variables, 
Dunnett’s multiple comparison test was used. GraphPad Prism v.6 software was used for 
statistical analysis and the differences were significant when the p value was 0.05 or less. 
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Figure legends 
 
Fig.1 D-PIGS induce cellular and humoral immune responses in human adenoid/tonsil 
cultures. 
(a) Schematic representation of the monomeric and polymeric human IgG1-cEDIII fusion 
protein and its interaction with high and low affinity Fc gamma receptors on APCs; 
further details of the structure of these molecules is described in Kim et al, PBJ, 
2017. Red represents cEDIII domain, while dark and light blue indicate CH2 and CH3 
domains of human IgG1, respectively. 
(b) Immunogenicity of D-PIGS in human tonsil cultures; shown are flow cytometric data 
of CFSE staining expressed as percentages of antigen-specific CD4 and CD8 
proliferating cells, IFN-γ and IgG concentrations in culture supernatants, induced by 
cEDIII alone, monomer/single chain (M/S) and polymer (P, D-PIGS). Data are shown 
as means +/- SEM from 8 patients. Statistical analysis was performed by ANOVA 
and Dunnett’s test, where * indicates differences < 0.05 and ** < 0.01.  
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Fig.2 Expression, purification and molecular fractionation of D-PIGS. 
(a) D-PIGS were expressed in N. benthamiana plants and the extracts analysed by 
Western blotting under reducing (R) or non-reducing (NR) conditions using anti-
dengue or anti-Fc gamma antibodies. ‘PC’ is the positive control (recombinant cEDIII 
or human IgG1, respectively). Lane 1: wild type plant extract; lane 2: unfractionated 
D-PIGS. Positions of the single chain (S), monomer (M) and polymers (P) are 
indicated.  
(b) SDS-PAGE and Commassie staining of fractionated D-PIGS. Lanes: 1. Commercial 
(Sigma) human sIgA; 2. Commercial (Sigma) human IgM; 3. Polymers and 4. 
Monomers. The schematics bellow indicate the expected molecular sizes for each 
fraction. 
(c) HPLC profile of D-PIGS. Unfractionated (upper panel) and fractionated (middle 
panel) D-PIGS. Indicated retention times were used to estimate the molecular 
weights of each fraction, based on gel-filtration protein standards (bottom panel). The 
fractionated D-PIGS were used in immunogenicity studies with tonsillar cultures 
(Fig.1b),  
 
Fig.3 Biacore analysis of binding of D-PIGS to Fc gamma receptors 
(a) Schematic representation of affinity vs avidity measurement  
(b) Affinity measurement of the interaction between immobilised (200RU) unfractionated 
D-PIGS and hIgG1 to CD64 (120, 60, 30, 15nM) and CD16a (800, 400, 100, 25, 
12.5nM). The panel on the right indicates calculated affinity constants (KD) for each 
interaction as calculated using either the 1:1 Langmuir model (CD64) or the ‘two-
state reaction’ model (CD16a). 
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(c) Binding (avidity) of unfractionated D-PIGS and human IgG1 to his-tag captured 
(immobilised) CD64, CD32a and CD16a receptors at a surface density of 
200pg/mm2. 
 
 
Fig.4 In vitro binding of D-PIGS to C1q and U937 cells 
(a) ELISA showing concentration dependent binding of various D-PIGS fractions to 
immobilised C1q. Shown are titration curves for 2-fold serial dilutions of indicated 
PIGS fractions of monomeric IgG binding to C1q immobilised at 10 μg/ml.  
(b) Flow cytometry analysis of the binding of D-PIGS to the surface of U937 human 
monocyte cells. Cells were incubated with 50 μg/ml of D-PIGS or human monomeric 
or heat aggregated IgG (AHG) IgG as the negative and positive control, respectively, 
for 2 h prior to analysis. Cells stained with the secondary antibody alone were used 
as the background control. 10,000 cells were analysed. 
 
Fig.5 IgG response in sera of CD64 Tg mice immunised with D-PIGS 
(a) Kinetics of the cEDIII specific IgG response in sera after each immunisation; 1:1000 
serum dilution was used. Shown are the means +/- SE for 5 mice/group. 
(b) End-point titres induced by D-PIGS determined in pooled sera from 5 mice at equal 
ratios. 
(c) and (d): IgG1 and IgG2a end-point titres in mice immunised with D-PIGS (determined 
as in b). 
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Fig.6: Neutralising activity of D-PIGS immune sera from mice 
Shown are the FRNT scatter plots and the titration curves from serial dilutions of immune 
sera from 5 mice for cEDIII alone and for D-PIGS, with or without alum. 50 % neutralisation 
cut off (perforated line) is indicated 
 
Fig. 7 Cellular immune responses induced by D-PIGS.  
(a)  T-cells were assessed for polyfunctionality after exposure to recall antigen in the 
CD4+ (left) and CD8+ (right) compartments. The gating strategy is shown in 
Supplementary data, Fig.S4. Pie charts depict sum total of 1 (blue), 2 (green), 3 
(yellow) and 4 cytokine-positive (red) responses, with values for specific cytokine 
combinations shown below.  
(b) Splenocytes were cultured for a further 5 days and assessed for intracellular 
expression of Ki67 in gated CD8+ cells, alongside extracellular levels of CD44 and 
CD62L. Shown are representative plots of proliferating cells.  
 
Supporting Information Legends 
 
Figure S1: Comparative analysis of D-PIGS expressed in wild type and ∆XF Benthamiana 
plants. 
Figure S2: Temperature stability of high molecular weight D-PIGS. 
Figure S3: Comparative analysis of low and high molecular weight D-PIGS.  
Figure S4: Dengue virus Neutralisation curves obtained with sera from mice immunised with 
cEDIII antigen alone or in combination with Alum 
Figure S5: Gating strategy for analysing T-cell intracellular cytokine staining by flow 
cytometry.  
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Figure S6: Gating strategy for analysing tonsillar T-cell proliferative response by CFSE 
staining and flow cytometry. 
Table S1: Kinetics data for D-PIGS interactions with IgG Fc receptors by surface plasmon 
resonance. 
Table S2: Time to 50% dissociation of antibody analyte from receptor ligand. 
Text S1: Functional characterisation of D-PIGS by C1q ELISA and cell surface binding; 
protocol description. 
Text S2: Humoral responses in sera of immunised mice; protocol description. 
Text S3: T-cell proliferation and IFN-γ; protocol description. 
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